Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
28.41 USD | -1.22% | +1.46% | +1.14% |
Financials (USD)
Sales 2024 * | 2.66B | Sales 2025 * | 2.94B | Capitalization | 12.81B |
---|---|---|---|---|---|
Net income 2024 * | 1.05B | Net income 2025 * | 1.08B | EV / Sales 2024 * | 6.98 x |
Net Debt 2024 * | 5.75B | Net Debt 2025 * | 5.94B | EV / Sales 2025 * | 6.38 x |
P/E ratio 2024 * |
12.1
x | P/E ratio 2025 * |
11.7
x | Employees | - |
Yield 2024 * |
3.12% | Yield 2025 * |
3.37% | Free-Float | 95.13% |
Latest transcript on Royalty Pharma plc
1 day | -1.22% | ||
1 week | +1.46% | ||
Current month | +2.56% | ||
1 month | -2.67% | ||
3 months | +2.53% | ||
6 months | +1.65% | ||
Current year | +1.14% |
Managers | Title | Age | Since |
---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 60 | 95-12-31 |
Terrance Coyne
DFI | Director of Finance/CFO | 42 | 09-12-31 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 23-09-20 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 95-12-31 |
Errol de Souza
BRD | Director/Board Member | 70 | 20-05-31 |
David Hodgson
BRD | Director/Board Member | 67 | 22-06-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
12.98% | 215 M€ | +10.80% | - | |
0.51% | 5 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-03 | 28.41 | -1.22% | 2,169,369 |
24-05-02 | 28.76 | +2.46% | 5,351,633 |
24-05-01 | 28.07 | +1.34% | 3,114,911 |
24-04-30 | 27.7 | -1.49% | 2,630,901 |
24-04-29 | 28.12 | +0.43% | 3,605,078 |
Delayed Quote Nasdaq, May 03, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.14% | 12.81B | |
+26.08% | 662B | |
+22.59% | 546B | |
-4.77% | 359B | |
+16.97% | 323B | |
+5.69% | 289B | |
+13.68% | 234B | |
+4.12% | 198B | |
-11.00% | 194B | |
+8.08% | 167B |
- Stock Market
- Equities
- RPRX Stock